ESMO 2014: The TRACERx study of lung cancer - European Medical Journal

ESMO 2014: The TRACERx study of lung cancer

Oncology
At ESMO 2014 Congress, Prof Charles Swanton (London Research Institute and UCL, UK) discusses TRAcking Cancer Evolution through therapy (TRACERx), which is a study that defines lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.